Ionis Pharmaceuticals competitors and similar companiesClear all
Ionis Pharmaceuticals's competitors and similar companies include Lannett, Intellia Therapeutics, Ultragenyx Pharmaceutical, Bluebird Bio, Sarepta Therapeutics, Reata Pharmaceuticals, Arrowhead Pharmaceuticals and Alnylam Pharmaceuticals.
 Ionis Pharmaceuticals Ionis Pharmaceuticals (formerly known as Isis Pharmaceuticals) is a company that discovers and develops RNA-targeted therapeutics. |  Intellia Therapeutics Intellia is developing therapeutic products to help people with genetic diseases. |  Ultragenyx Pharmaceutical Ultragenyx Pharmaceutical focuses on the development of various products for the treatment of rare and ultra-rare diseases. |  Sarepta Therapeutics Sarepta Therapeutics is a biopharmaceutical company focused on developing innovative RNA-targeted therapeutics. |  Reata Pharmaceuticals Reata Pharmaceuticals is a biopharmaceutical company that develops therapeutics for patients with serious or life-threatening diseases. |  Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. |  Alnylam Pharmaceuticals Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. | |||
Founding Date | Founding Date 1989 | Founding Date 1942 | Founding Date 2014 | Founding Date 2010 | Founding Date 1992 | Founding Date 1980 | Founding Date 2002 | Founding Date 2004 | Founding Date 2002 |
Type | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public |
Tags | |||||||||
Locations | Locations Carlsbad, US HQ | Locations Trevose, US HQ Philadelphia, US | Locations Cambridge, US HQ | Locations Novato, US HQ | Locations Cambridge, US HQ Boulogne Billancourt, FR Berlin, DE Dublin, IE Milano, IT Chiyoda City, JP see more | Locations Plano, US HQ Irving, US Plano, US | Locations Pasadena, US HQ Madison, US San Diego, US | Locations Cambridge, US HQ Paris, FR Milano, IT Chiyoda City, JP Amsterdam, NL Stockholm, SE Zug, CH see more | |
Employees | Employees 7577% decrease | Employees 81015% decrease | Employees 27028% increase | Employees 74021% increase | Employees 1,2134% increase | Employees 74349% increase | Employees 22079% increase | Employees 13416% increase | Employees 1,32324% increase |
Valuation ($) | Valuation ($) 6.5 b | Valuation ($) 19.5 m | Valuation ($) 4.2 b | Valuation ($) 2.8 b | Valuation ($) 443.8 m | Valuation ($) 9.6 b | Valuation ($) 914.5 m | Valuation ($) 3.5 b | Valuation ($) 23.9 b |
Twitter followers | Twitter followers 4.2 k | Twitter followers N/A | Twitter followers 9.3 k | Twitter followers N/A | Twitter followers 10.5 k | Twitter followers 4.4 k | Twitter followers 1.3 k | Twitter followers 3.1 k | Twitter followers 15.7 k |
Number of tweets (last 30 days) | Number of tweets (last 30 days) 13 | Number of tweets (last 30 days) N/A | Number of tweets (last 30 days) 7 | Number of tweets (last 30 days) N/A | Number of tweets (last 30 days) 17 | Number of tweets (last 30 days) 22 | Number of tweets (last 30 days) 12 | Number of tweets (last 30 days) 9 | Number of tweets (last 30 days) 36 |
Average likes per tweet (last 30 days) | Average likes per tweet (last 30 days) 3.8 | Average likes per tweet (last 30 days) N/A | Average likes per tweet (last 30 days) 23.3 | Average likes per tweet (last 30 days) N/A | Average likes per tweet (last 30 days) 15.8 | Average likes per tweet (last 30 days) 14.9 | Average likes per tweet (last 30 days) 2.7 | Average likes per tweet (last 30 days) 17.7 | Average likes per tweet (last 30 days) 8.9 |
Percentage of tweets with engagement (last 30 days) | Percentage of tweets with engagement (last 30 days) 100% | Percentage of tweets with engagement (last 30 days) N/A | Percentage of tweets with engagement (last 30 days) 100% | Percentage of tweets with engagement (last 30 days) N/A | Percentage of tweets with engagement (last 30 days) 100% | Percentage of tweets with engagement (last 30 days) 90.91% | Percentage of tweets with engagement (last 30 days) 75% | Percentage of tweets with engagement (last 30 days) 100% | Percentage of tweets with engagement (last 30 days) 97.22% |
Alexa Website Rank | Alexa Website Rank 551736 | Alexa Website Rank 394906 | Alexa Website Rank 511026 | Alexa Website Rank 493642 | Alexa Website Rank 438682 | Alexa Website Rank 448530 | Alexa Website Rank 267230 | Alexa Website Rank 436940 | Alexa Website Rank 376993 |
Employee Rating | Employee Rating 3.6 | Employee Rating 2.1 | Employee Rating 4 | Employee Rating 4.3 | Employee Rating 3.6 | Employee Rating 4.1 | Employee Rating 3.6 | Employee Rating 3.9 | Employee Rating 4.2 |
Financial | |||||||||
Revenue (est.) | Revenue (est.) $810.5m (FY, 2021) | Revenue (est.) $340.6m (FY, 2022) | Revenue (est.) $33.1m (FY, 2021) | Revenue (est.) $351.4m (FY, 2021) | Revenue (est.) $3.7m (FY, 2021) | Revenue (est.) $701.9m (FY, 2021) | Revenue (est.) $11.5m (FY, 2021) | Revenue (est.) $138.3m (FY, 2021) | Revenue (est.) $844.3m (FY, 2021) |
Cost of goods | Cost of goods $10.8m (FY, 2021) | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A | Cost of goods $115m (FY, 2021) |
Net income | Net income ($28.6m) (FY, 2021) | Net income ($231.6m) (FY, 2022) | Net income ($267.9m) (FY, 2021) | Net income ($454m) (FY, 2021) | Net income ($819.4m) (FY, 2021) | Net income ($418.8m) (FY, 2021) | Net income ($297.4m) (FY, 2021) | Net income ($140.8m) (FY, 2021) | Net income ($852.8m) (FY, 2021) |
Operating ⚠ | |||||||||
Patents Issued | Patents Issued N/A | Patents Issued N/A | Patents Issued N/A | Patents Issued N/A | Patents Issued N/A | Patents Issued N/A | Patents Issued 240 (FY, 2016) | Patents Issued 359 (FY, 2016) | Patents Issued N/A |
Phase I Trials Products | Phase I Trials Products 6 (FY, 2020) | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products 2 (FY, 2016) | Phase I Trials Products N/A | Phase I Trials Products N/A |
Phase II Trials Products | Phase II Trials Products 24 (FY, 2020) | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products 4 (FY, 2016) | Phase II Trials Products N/A | Phase II Trials Products N/A |
Phase III Trials Products | Phase III Trials Products 6 (FY, 2020) | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products 1 (FY, 2016) | Phase III Trials Products N/A | Phase III Trials Products N/A |
Funding | |||||||||
Total funding raised | Total funding raised N/A | Total funding raised N/A | Total funding raised N/A | Total funding raised $ 200.1m | Total funding raised $ 409m | Total funding raised N/A | Total funding raised $ 468.9m | Total funding raised $ 147.1m | Total funding raised $ 1.5b |
For sources of this data, please see the company profile
View company profiles
Lannett
HQ
Trevose, US
Employees
810↓ 15% decrease
Lannett is a company that specializes in pharmaceutical product families.
View companyIntellia Therapeutics
HQ
Cambridge, US
Employees
270↑ 28% increase
Intellia is developing therapeutic products to help people with genetic diseases.
View companyUltragenyx Pharmaceutical
HQ
Novato, US
Employees
740↑ 21% increase
Ultragenyx Pharmaceutical focuses on the development of various products for the treatment of rare and ultra-rare diseases.
View company
Bluebird Bio
HQ
Cambridge, US
Employees
1,213↑ 4% increase
Bluebird Bio is a developer of gene therapies for severe genetic diseases and cancer.
View company